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Abstract
Enterovirus 71 (EV71) causes hand, foot and mouth disease, a mild and self-limited illness
that is sometimes associated with severe neurological complications. EV71 neurotropic
determinants remain ill-defined to date. We previously identified a mutation in the VP1 cap-
sid protein (L97R) that was acquired over the course of a disseminated infection in an immu-
nocompromised host. The mutation was absent in the respiratory tract but was present in
the gut (as a mixed population) and in blood and cerebrospinal fluid (as a dominant species).
In this study, we demonstrated that this mutation does not alter the dependence of EV71 on
the human scavenger receptor class B2 (SCARB2), while it enables the virus to bind to the
heparan sulfate (HS) attachment receptor and modifies viral tropism in cell lines and in respi-
ratory, intestinal and neural tissues. Variants with VP197L or VP197R were able to replicate to
high levels in intestinal and neural tissues and, to a lesser extent, in respiratory tissues, but
their preferred entry site (from the luminal or basal tissue side) differed in respiratory and
intestinal tissues and correlated with HS expression levels. These data account for the viral
populations sequenced from the patient’s respiratory and intestinal samples and suggest
that improved dissemination, resulting from an acquired ability to bind HS, rather than spe-
cific neurotropism determinants, enabled the virus to reach and infect the central nervous
system. Finally, we showed that iota-carrageenan, a highly sulfated polysaccharide, effi-
ciently blocks the replication of HS-dependent variants in cells and 2D neural cultures. Over-
all, the results of this study emphasize the importance of HS binding in EV71 pathogenesis
and open new avenues for the development of antiviral molecules that may prevent this vir-
us’s dissemination.
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Author summary
Enterovirus 71 (EV71) has been the cause of major hand-foot-and-mouth disease out-
breaks, particularly in the Asia-Pacific region. However, the recent emergence of severe
neurological cases associated with EV71 infection in Europe and the lack of an efficient
vaccine or antiviral agent to fight EV71 infections highlight two critical needs: (A) the
identification of ill-defined viral factors that contribute to viral dissemination and patho-
genesis in humans and (B) the development of effective antiviral strategies. Herein, based
on clinical observation in an immunocompromised host, we have demonstrated that
heparan sulfate attachment receptor played a critical role in EV71 virulence and that “in
host” EV71 adaptation to a heparan sulfate-dependent virus was likely responsible for its
dissemination. To our knowledge, this is the first study highlighting the key determinants
of EV71 dissemination based on a clinical case and proposing a new therapeutic approach
against EV71 neurological diseases.
Introduction
Enterovirus 71 (EV71) is one of a limited number of enterovirus genotypes that have the ability
to infect the central nervous system (CNS) [1–3] and has emerged as a major health-care threat
across the Asia-Pacific region [4–7]. Although this virus is typically associated with mild hand,
foot and mouth disease (HFMD) epidemics, EV71 has been increasingly associated with neu-
rological disorders that range from aseptic meningitis with or without pulmonary edema to
brain stem encephalitis and poliomyelitis-like acute flaccid paralysis, particularly among chil-
dren less than 6 years old [8–10]. EV71 transmission depends on hygiene, water quality, and
the extent of crowding [11]. EV71 is typically transmitted through fecal-oral routes, although
transmission via respiratory secretions also frequently occurs, particularly in countries with
high standard sanitation [12, 13].
Following infection, EV71 predominantly replicates in the intestinal mucosa and, to a lesser
extent, in the respiratory mucosa [5, 14]. Subsequently, the virus can enter the bloodstream
and disseminate to a variety of organs, including the central nervous system (CNS) [15]. EV71
dissemination to the CNS remains a rare event and the viral neurotropic determinants remain
ill-defined, despite extensive epidemiological studies and experimentation in animal models.
EV71 tissue tropism may be modulated by its ability to bind to a variety of receptors [16].
The human scavenger receptor class B2 (SCARB2), a major transmembrane lysosomal protein,
is ubiquitously expressed and is the best studied receptor [17]. In the human CNS, SCARB2 is
expressed on neurons and glial cells [18], and a transgenic mouse model expressing human
SCARB2 has exhibited susceptibility to EV71 infection and the development of ataxia, paraly-
sis and death [19]. The second EV71 entry receptor, P-selectin glycoprotein ligand-1 (PSGL-
1), is expressed exclusively on leukocytes and is only bound by certain EV71 strains [20, 21].
Finally, attachment molecules, such as heparan sulfate glycosaminoglycan (HS) [22], sialic
acids [23], nucleolin [24], vimentin [25] and annexin II [26] also enhance EV71 infectivity and
may contribute to viral dissemination and neurotropism. Residues that are crucial for the
binding of EV71 to certain of these receptors have been mapped on the VP1 viral capsid pro-
tein. For instance, 172Q and adjacent amino acids in the EF loop are required for binding to
human SCARB2 and for efficient infection of cells expressing this receptor [27] while K98E,
E145A and L169F substitutions confer binding ability to murine SCARB2 [28]. Similarly,
EV71 strains with a glycine or a glutamine at position 145 of VP1 are able to bind PSGL-1,
while strains with a glutamate at this position are not [21]. Binding of EV71 to annexin II has
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been mapped to the BC loop region of VP1 (residues 40–100) [26]. Finally, positively charged
residues at the 5-fold axis of EV71 capsids (VP1 162K, 242K, and 244K) appear to be essential
for attachment to HS. When these residues are mutated, compensatory mutations (E98A,
T100K and Q145R-T237N) can restore binding. Similarly, strains with 98E and 145E are poor
HS binders, while E98K restores binding [29]. These observations are based on in vitro adapted
EV71 isolates and do not address the in vivo significance of dissemination and neurotropism.
In addition, the implication of immune escape mutations may add a level of complexity. VP1
residues 98 and 145 have been shown to be under positive selection and may be targeted by
neutralizing antibodies [30, 31]. Finally, EV71 virulence determinants that have been identi-
fied in animal models contradict epidemiological studies in humans. VP1 residue 145E was
shown to be a virulence factor for both cynomolgus monkeys [31, 32] and mice [33, 34], while
isolates with 145G/Q are also frequently associated with severe neurological disease in humans
[35–38]. Mutations in other genomic regions may explain these apparent contradictions.
We previously isolated EV71 from an immunocompromised patient with disseminated dis-
ease. Genomic analysis revealed that this clinical strain clusters with EV71 in the human EV-A
species and is related to the subgenogroup C1. Comparison of five full-length genomes
sequenced directly from respiratory, gastrointestinal, nervous system and blood specimens
highlighted a critical non-synonymous single amino acid change within the EV71 VP1 BC
loop (L97R) that could potentially lead to dissemination in natural infections. EV71-VP197R,
which was absent in the respiratory sample, was present as a dominant population in blood
and cerebrospinal fluid samples and as a mixed population (EV71-VP197R/L) in the stool sam-
ple [39]. However, the mechanisms by which the mutant virus could disseminate are not clear.
In this study, we investigated the capacity of EV71-VP197L and EV71-VP197R to bind and
mediate infection in different cell lines and in 3D reconstituted respiratory, intestinal and neu-
ral tissues. We demonstrated that both derivatives are dependent on SCARB2 for effective
infection, while their specific tropism is linked to a different ability to bind HS and further cor-
relates with the expression level of this attachment receptor in the tested tissues. This study
provides new insight regarding HS binding as a critical determinant of EV71 dissemination in
humans and opens the door to antiviral strategies aimed at preventing EV71 in-host adapta-
tion and dissemination.
Results
EV71-VP197R and EV71-VP197L variants exhibit different cell tropism
We previously showed that the VP1 L97R mutation conferred a binding advantage in RD and
Vero cells. In addition, we showed in vitro that this mutation was associated with a second
non-conservative mutation (E167G/A) in the VP1 EF loop [39]. To define the role of these
mutations more precisely, we generated 4 infectious clones with distinct combinations of each
of the mutations (Table 1).
Viral stocks were prepared in monkey kidney cells (Vero) and titrated in Vero, colorectal
carcinoma (Caco-2), rhabdomyosarcoma (RD) and neuroblastoma cells (SH-SY5Y). After
4 days of infection, viruses were sequenced from each cell line. EV71-VP197L167G and
EV71-VP197R167E viral stocks were unstable independent on the cell line (Table 1) and thus
could not be amplified and purified in sufficient quantities to be used in functional assays.
EV71-VP197L167E (originally isolated from the lower respiratory tract sample of the patient
with a disseminated infection) and EV71-VP197R167G (in vitro adapted from EV71-VP197R167E,
which was originally isolated from the stool, cerebrospinal fluid and blood of the patient)
were thus used for all further investigations. Titration showed that EV71-VP197L167E and
EV71-VP197R167G exhibited differential cell tropism, with significantly enhanced replication
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being observed for EV71-VP197R167G in RD and SH-SY5Y cells (Fig 1). Notably, the RNA load
measured in the stocks prepared in Vero cells was comparable for the two viruses (12.38 log
RNA copies/ml for EV71-VP197R167G and 12.30 log RNA copies/ml for EV71-VP197L167E).
EV71-VP197R167G and EV71-VP197L167E infections are dependent on
SCARB2
As SCARB2 plays a critical role for EV71 infection [17], we investigated whether the differen-
tial cell tropism of the two variants is linked to a different dependence on this receptor. We
used the CRISPR/Cas9 system to knockout SCARB2 in Caco-2 and RD cells, two cell lines
presenting different susceptibilities to the two variants (Fig 1). A striking reduction in viral
titers was observed in SCARB2 knockout RD and Caco-2 cells for EV71-VP197L167E and
EV71-VP197R167G (Fig 2) suggesting that both variants depend on this receptor for effective
infection regardless of the cell line. This was also shown by transfection of human SCARB2 in
mouse L929 cells that are non-permissive for infection by EV71 [17]. Exogenous expression of
human SCARB2 conferred susceptibility to both EV71-VP197L167E and EV71-VP197R167G (S1
Fig) confirming that the two viruses are dependent on SCARB2.
Differential cell tropism of EV71-VP197R167G and EV71-VP197L167E is
related to differential use of the heparan sulfate attachment receptor
We then investigated the implication of another ubiquitously expressed receptor, the HS
attachment receptor, in this observed differential cell tropism. We measured the amount of
EV71-VP197R167G and EV71-VP197L167E viruses bound to untreated cells or cells pretreated
with heparinase III (Fig 3A). EV71-VP197R167G exhibited a binding advantage over EV71-V-
P197L167E in RD, Vero and SH-SY5Y cells but not in Caco-2 cells. This advantage was sup-
pressed after cleavage of HS from the cell surface (Fig 3A, left panel). In contrast,
EV71-VP197L167E did not show a significant difference in any cell line (Fig 3A, right panel).
To confirm this observation, competition experiments were performed with a viral stock
(EV71-VP197R/L-167G/E) containing equivalent amounts of each derivative. The competition
was run under 3 conditions: using untreated cells, using cells having surface HS digested with
heparinase, or using a viral population that was pretreated with heparin, a soluble HS ana-
logue. Both binding (1 hour post-infection [hpi]) and replication (24 hpi) efficiencies were
monitored by real time-quantitative polymerase chain reaction (RT-qPCR), and the dominant
species was characterized by Sanger sequencing for each binding (Fig 3B) and replication
condition (Fig 3C). The overall binding was lower for the mixed population than for the
EV71-VP197R167G stock (Fig 3B versus 3A). Accordingly, the pretreatment of cells with hepari-
nase reduced viral binding less significantly, while viral replication was affected in SH-SY5Y,
Table 1. Schematic representation of the 4 infectious clone constructs and spontaneous mutations arising in culture.





















Virus sequenced from the bronchoalveolar lavage of a patient with disseminated EV71 infection.
Virus sequenced from the stool, blood and cerebrospinal fluid of a patient with disseminated EV71 infection [39]. +, positive charge; -, negative charge; o, neutral
charge.
https://doi.org/10.1371/journal.ppat.1007190.t001
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Vero and Caco-2 cells. Sanger sequencing of the entire VP1 region after binding showed that
in Vero, SH-SY5Y and RD cells, EV71-VP197R167G (with R at position 97 encoded by CGC
and G at position 167 encoded by GGG) was the dominant variant in non-treated conditions,
which was not the case in Caco-2 cells, where EV71-VP197L167E (with L at position 97 encoded
by CTC and E at position 167 encoded by GAG) and EV71-VP197L167G were dominant (Fig
3C). Upon heparinase treatment, the dominant consensus sequence shifted towards
EV71-VP197R/L167G/E, EV71-VP197L167G/E or EV71-VP197L167E in binding and replication
assays. Notably, viral species with a positive charge at VP1 position 98 (K encoded by GAA
instead of E encoded by AAA) emerged after treatment of SH-SY5Y, RD and Caco-2 cells with
heparinase (Fig 3C and 3D). Pre-incubation of viruses with heparin also resulted, although in
a less stringent manner, in a shift of the dominant population from EV71-VP197R167G to a
mixed EV71-VP197R/L167G/E population, except after replication in SH-SY5Y and RD cells.
To determine if the improved binding and replication of EV71-VP197R167G in cells corre-
lated with HS expression levels, quantification of HS expression was assessed by immunofluo-
rescence (Fig 3D and 3E). SH-SY5Y, RD and Vero cell lines strongly express HS, while Caco-2
showed low HS expression.
Fig 1. Differential cell tropism EV71-VP197R167G and EV71-VP197L167E. The mean (N = 2) viral titers (±SEM) expressed as log TCID50/ml (median
tissue culture infective dose) obtained 4 dpi are indicated. P<0.05.
https://doi.org/10.1371/journal.ppat.1007190.g001
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A recent publication showed that variants with VP1 E167G do not bind heparin [29], and
the differential binding and replication of EV71-VP197R167G confirmed our previous observa-
tions with EV71-VP197R167E in SH-SY5Y and Vero cells [39], indicating that the acquired HS
binding ability is due only to the L97R substitution.
Finally, we confirmed the different affinity of EV71-VP197R167G and EV71-VP197L167E for
HS using a heparin sepharose binding assay. After incubation of a mixed viral stock (EV71-
VP197R/L-167G/E) composed of 50% of each derivative with sepharose beads, we sequenced the
viral populations present in the non-heparin-binding population (flow-through) or in the hep-
arin-binding population (eluate) (Fig 3E). As expected, EV71-VP197L167E was highlighted in
the non-heparin-binding population, while EV71-VP197R167G was detected in the heparin-
binding population.
Differential tissue tropism of EV71-VP197R167G and EV71-VP197L167E
variants is related to differential use of the heparan sulfate attachment
receptor
To better replicate the viral tropism observed in the patient, infection assays were performed
with EV71-VP197R167G, EV71-VP197L167E and EV71-VP197R/L167G/E in complex tissue models,
in vitro reconstituted from human primary cells, that mimic the upper respiratory tract, small
intestine and neural tissues composed of neurons and glial cells.
Respiratory tissues. As only viruses with VP1 97L were detected in the patient bronchoal-
veolar lavage, the replication of EV71-VP197R167G, EV71-VP197L167E and EV71-VP197R/L167G/E
was compared in 3D reconstituted human upper (Fig 4A MucilAir) and lower (Fig 4B Smal-
lAir ) airway epithelia cultured at an air-liquid interface. These tissues faithfully reproduce the
pseudostratified architecture of the upper and lower airway epithelia composed of ciliated
cells, mucus secreting cells (as well as club cells in the lower airway) and basal cells (Fig 4C and
4D, upper panels) [40, 41]. Viral suspensions were applied apically (air exposed side) or basally
(liquid exposed side) for 4 hours before removal of unbound viruses by extensive washing.
Fig 2. SCARB2 is necessary for effective infection by EV71-VP197R167G and EV71-VP197L167E. A) Mean (N = 2)
viral titers (±SEM) expressed as log TCID50/ml (median tissue culture infective dose) obtained 5 dpi in cells expressing
(control) or not (ΔSCARB2) SCARB2. Wells with less than 50 infected cells were considered as negative. B) Western
blot showing SCARB2 expression in ΔSCARB2 cells and control cells. P<0.0001, P<0.01, P<0.05.
https://doi.org/10.1371/journal.ppat.1007190.g002
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Each day afterwards, apically released viruses were collected and basal medium was changed.
Viruses released apically at day 5 pi were quantified by RT-qPCR (Fig 4A and 4B). Overall rep-
lication was low in both tissue types compared to typical respiratory EVs, such as EV-D68 or
rhinoviruses [40, 42], however the infectivity of viruses collected at day 5 pi was confirmed by
productive infection in RD cells. No significant difference was observed in the level of replica-
tion of EV71-VP197R167G and EV71-VP197L167E after apical inoculation of MucilAir (Fig 4A)
or SmallAir (Fig 4B). Nevertheless, sequencing of the viral population collected at 5 dpi
highlighted that, when inoculated together, EV71-VP197L167E outcompeted EV71-VP197R167G
Fig 3. Differential cell tropism of EV71-VP197R167G and EV71-VP197L167E is linked to HS binding and correlates
with its expression level at the cell surface. (A). Binding of EV71-VP197R167G (left panel) and EV71-VP197L167E (right
panel) in the presence or absence of HS. Binding (B) and replication (C) of a viral stock composed of equivalent
amounts of EV71-VP197R167G and EV71-VP197L167E in different cell lines and under conditions preventing attachment
to HS. Viral loads were measured by RT-qPCR (real-time quantitative reverse transcription PCR) in whole cell extracts
for binding assay and both cell extracts and supernatants for replication assay, and expressed as the mean (±SEM, N2)
relative to the EV71-VP197R167G load in non-treated RD cells (100%). (D). Quantification of HS-expressing (positive)
cells was achieved through an analysis using MetaMorph software (left panel) based on the immunofluorescence
labeling (right panel) of HS attachment receptors at the surface of Vero, RD, SH-SY5Y cells and Caco-2 cells. More than
500 cells were included in the analysis. Scale bar = 20 μm. (E) Binding of EV71-VP197R/L167G/E to heparin sepharose
beads. Viral population present in the input, flow-through and elute population was characterized by sequencing.
P<0.0001, P<0.001, P<0.01, P<0.05. For B, C and E, the frequency plot [http://weblogo.berkeley.edu/] of
codons encoding VP1 aa 97, 98 and 167 are shown and are representative of biological replicates (N2). Arginine (R) at
position 97 is encoded by CGC, Leucine (L) by CTC; Glutamate (E) at position 98 is encoded by GAA, Lysine (K) by
AAA; Glycine (G) at position 167 is encoded by GGG, Glutamate (E) by CTC.
https://doi.org/10.1371/journal.ppat.1007190.g003
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(Fig 4A and 4B). In contrast, after basal infection, EV71-VP197R167G showed a net replication
advantage in both individual and competition replication assays.
These results correlate with high expression of HS at the basal tissue side and notably low
HS expression at the apical side (Fig 4C and 4D). Interestingly, the expression of SCARB2
showed the opposite pattern with high expression at the apical tissue side and low expression
at the basal side (Fig 4C and 4D).
Intestinal tissues. As a mixed population of viruses with VP1 97L and VP1 97R was
highlighted in the patient’s stool, the experimental approach used for respiratory tissues was
applied to assess the replication abilities of EV71-VP197R167G and EV71-VP197L167E in 3D
reconstituted human small intestine tissues (EpiIntestinal, Mattek) cultured at the air-liquid
interface (Fig 5). In this tissue culture model, that reproduces the cellular composition of the
small intestine with enterocytes, paneth cells, M cells, tuft cells and intestinal stem cells, viral
loads were more than 2 log higher than those measured in respiratory tissues (Fig 5A versus
Fig 4A and 4B). For small intestine tissues as for respiratory tissues, there was no significant
difference between the replication of EV71-VP197R167G and EV71-VP197L167E 5 dpi for the api-
cal inoculation (Fig 5A), while for the basal inoculation, EV71-VP197R167G replicated signifi-
cantly better than EV71-VP197L167E and systematically outcompeted the latter variant in
competition. However, in contrast to observations made in respiratory tissues, EV71-V-
P197L167E did not outcompete EV71-VP197R167G after the apical infection, and both popula-
tions were present 5 dpi in a mixed viral population. These data are in agreement with the
Fig 4. Replication of EV71-VP197R167G, EV71-VP197L167E and EV71-VP197R/L167G/E in reconstituted airway
epithelia developed from the upper (A) and lower (B) respiratory tract and HS/SCARB2 expression in the same
tissues (C -D). (A-B) Viral loads were measured by RT-qPCR 5 dpi in the apically collected washes of the apically or
basally inoculated tissues and are expressed as the mean ±SEM (N2). P<0.001, P<0.01, P<0.05. Frequency
plots are shown on the right (see Fig 3 for details) (C-D) Tissue sections were colored with hematoxylin and eosin
(upper panel) or labeled by immunofluorescence. SCARB2 is stained in green, HS in red and cell nuclei in blue. Scale
bar = 20 μm.
https://doi.org/10.1371/journal.ppat.1007190.g004
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expression of HS in the tissue, with the attachment receptor being expressed both at the apical
and basal side of the tissue, although with higher concentration at the basal tissue side (Fig 5B
and 5C). Again, for these tissues as for respiratory tissues, SCARB2 expression is more abun-
dant at the apical tissue side (Fig 5B).
2D and 3D engineered neural cultures. Since only EV71 with VP1 97R was sequenced
from the patient’s CSF, the replication of the different variants was also compared in engi-
neered 2D (Fig 6A) and 3D (Fig 6B) neural tissues containing a mixed population of mature,
functional neurons and glial cells. Viral loads were measured in 2D culture lysates at 1 hpi and
5 dpi and in 3D tissue lysates at 4 hpi and 5 dpi. EV71-VP197R167G, EV71-VP197L167E and
EV71-VP197R/L167G/E replicated efficiently in both types of cultures and without significant dif-
ference 5 dpi. Notably, EV71-VP197R167G viral loads were significantly higher 4 hpi in 3D tis-
sues. Upon infection with a mixed population, this variant was also dominant at 1 hpi and 4
hpi in 2D and 3D tissues, respectively (Fig 6A and 6B), as well as at 1 dpi in 2D cultures (Fig
7B). However, the replication fitness of EV71-VP197L167E was greater in competition experi-
ments at 5 dpi. HS expression is abundant in both models, supporting the selection of
EV71-VP197R167G at early time points but not the dominance of EV71-VP197L167E 5 dpi (Fig
6C). Of note both HS (S2A and S2B Fig) and SCARB2 (S2C and S2D Fig) are highly expressed
in neurons and glial cells.
Fig 5. Replication of EV71-VP197R167G, EV71-VP197L167E and EV71-VP197R/L167G/E in reconstituted small
intestine tissues (A) and HS/SCARB2 expression in the same tissues (B and C). (A) Viral loads were measured by
RT-qPCR 5 dpi in the apically collected washes of the apically or basally inoculated tissues and are expressed as the
mean (±SEM) N = 2. P<0.01, P<0.05. The frequency plots are shown on the right (see Fig 3 for details) (B) Tissue
sections were colored with hematoxylin and eosin (upper panel) or labeled by immunofluorescence. SCARB2 is
stained in green, HS in red and cell nuclei in blue. Scale bar = 20 μm. (C) Quantification of HS expression at the apical
and basal surface of intestinal tissues was achieved through an analysis using MetaMorph software based on the
immunofluorescence labeling of HS attachment receptor in sectioned tissues.
https://doi.org/10.1371/journal.ppat.1007190.g005
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Iota-carrageenan specifically inhibits infection by EV71-VP197R167G
Because of the acquired ability of EV71-VP197R167G to bind HS, its sensitivity to iota-carra-
geenan (ı-carrageenan), a highly sulfated polysaccharide, was investigated and compared to
the sensitivity of EV71-VP197L167E in Vero and 2D neural cultures. As expected, EV71-
VP197R167G infection was strongly inhibited by ı-carrageenan in Vero cells (IC50 = 17.8 μg/ml),
whereas EV71-VP197L167E infection was only slightly affected by the treatment (IC50>200
μg/ml) (Fig 7A). Similar results were obtained in neural cultures, where the infection of
Fig 6. Replication of EV71-VP197R167G, EV71-VP197L167E and EV71-VP197R/L167G/E in 2D (A) and 3D (B) neural tissues and HS/SCARB2 expression in the same
2D tissues (C). (A-B) Viral load was measured by RT-qPCR and expressed as the mean (±SEM). (N = 2). P<0.0001, ++P<0.01 or #P<0.05. (+relative to
EV71-VP197L167E and
# relative to EV71-VP197R/L167G/E at the same time point). The frequency plots are shown on the right (see Fig 3 for details) (C) 2D neural cultures
were labeled by immunofluorescence. SCARB2 is stained in green, HS in red and cell nuclei in blue. Scale bar = 20 μm.
https://doi.org/10.1371/journal.ppat.1007190.g006
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EV71-VP197R167G and EV71-VP197R/L167G/E was inhibited up to 90% in a dose-dependent
manner. EV71-VP197L167E infectivity was also inhibited but to a lesser extent (up to 50%).
Treatment of the mixed viral population altered the dominant sequence from EV71-
VP197R167G at 1 dpi towards EV71-VP197R/L167G/E (Fig 7B).
Discussion
In 2012, we reported an EV71 genogroup C1 disseminated infection in an immunocompro-
mised patient treated with rituximab who was hospitalized with respiratory and neurological
symptoms [39]. Although EV71 genogroup C1 infections have not been associated with severe
diseases in the past, several complicated cases have been recently reported in Europe, under-
scoring the importance of defining EV71 virulence determinants [43, 44]. By sequencing the
full genome of the virus from different samples, we identified the acquisition of a non-conser-
vative mutation in VP1 (L97R), which was absent at the beginning of the infection in the respi-
ratory tract but was present in a mixed population in the gastrointestinal tract and became
dominant in the blood and CSF at later time points. We showed that this mutation conferred a
binding advantage to the virus in certain cell lines. In this study, we extended these findings
and showed that the VP1 L97R substitution, as well as an associated mutation (VP1 E167G)
observed after in vitro culturing, confers an ability of the virus to use HS as an attachment
receptor while it does not alter the dependence of the virus on the ubiquitously expressed
SCARB2 entry receptor. Tan and colleagues recently showed that variants with VP1 E167G do
not bind heparin [29]. In addition, in our previous publication, we observed the same binding
advantage of the VP197R mutant in neuroblastoma and Vero cells that was observed in this
study with the VP197R167G mutant [39]. This strongly suggests that the VP1 L97R mutation
confers an HS binding ability, while the VP1 E167G mutation has a stabilizing function as pro-
posed previously based on VP1 3D structure [39]. Interestingly, after competition between
EV71-VP197L167E and EV71-VP197R167G for binding and replication in cells pretreated with
heparinase, EV71-VP197R was excluded from the viral population, while a new variant
(EV71-VP198K) which is also known to promote HS binding [29], emerged. Thus, it is very
likely that after cleavage with heparinase at the 1!4 linkages between hexosamine and glucu-
ronic acid residues, HS is still bound by EV71-VP198K but not by EV71-VP197R, suggesting
that these two variants present different HS binding specificities.
Fig 7. Viral infectivity of EV71-VP197R167G and EV71-VP197L167E in Vero cells (A) and of EV71-VP197R167G,
EV71-VP197L167E and EV71-VP197L/R167E/G in neural cells (B) in the presence of increasing doses of ı-carrageenan.
The percent of infection was measured by an immunocytochemistry assay in Vero cells (A) and by RT-qPCR on cell
lysate 1 dpi in neural cells (B) and expressed as the mean (±SEM) compared to non-treated viruses. (N = 2).
P<0.005. The frequency plots are shown on the right (see Fig 3 for details).
https://doi.org/10.1371/journal.ppat.1007190.g007
Heparan sulfate binding as a determinant of enterovirus 71 tropism
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007190 August 3, 2018 11 / 25
To assess EV71 replication in vivo in the gastrointestinal and respiratory tracts and in the
CNS, we analyzed the replication of HS-dependent (EV71-VP197R167G) and independent
(EV71-VP197L167E) variants in relevant tissue culture models that mimicked the upper and
lower respiratory airway epithelia, intestinal and neural tissues. To reproduce natural infection
routes, we inoculated intestinal and respiratory tissue cultures that grow at an air-liquid inter-
face from the apical (corresponding to the lumen) or basal (corresponding to the blood-borne)
tissue sides. A comparison of viral growth of HS-dependent and HS-independent variants and
competition experiments highlighted that HS-dependent variants had improved access to
respiratory and intestinal tissues from the basal tissue side, where HS is highly expressed, while
HS-independent variants show improved replication after infection from the air-exposed side
of respiratory tissues, where HS is only slightly present, in line with previous publications [45,
46]. Infection from the luminal side of intestinal tissues sustained efficient replication of both
variants and correlated with intermediate expression of HS at this side. We also highlighted
high expression of SCARB2 at the apical side of respiratory and intestinal tissues and low
expression at the basal side. HS may thus be necessary in tissues with low SCARB2 expression
to concentrate the virus at the cell surface and promote subsequent interaction with SCARB2.
This would explain why HS-dependent variants infect the basal side of respiratory and intesti-
nal tissues better than HS-independent variants.
Our findings in respiratory and intestinal tissues correlate with the viral populations iso-
lated from the different specimens of the patient. We only observed an HS-independent vari-
ant in the bronchoalveolar lavage of the patient, a sample collected from the luminal side of the
respiratory tissue. Importantly, sequencing of EV71 that was detected in bronchoalveolar
lavages from two other immunosuppressed patients who presented neurological complications
in Switzerland also identified viruses from the same genogroup and with the same VP1
sequence (GenBank accession numbers MH256663 and MH256664). Of note in these 2 cases
as in our case, the infecting virus had a glutamate at position 145, a residue known to confer
poor HS binding ability [29]. This suggests that HS-independent variants may be preferentially
transmitted via the respiratory route.
We observed a mixed viral population in the stool of the patient, a sample that reflects viral
population isolated from the luminal side of the gastrointestinal tract. A mixed viral popula-
tion was also obtained after apical inoculation of intestinal tissue cultures with a viral popula-
tion composed of EV71-VP197L167E and EV71-VP197R167G. Since both ex vivo and in vivo
intestinal tissues are the favored site of EV71 replication, and since these tissues express HS at
the basal and apical surface, it is very likely that the emergence of an HS-dependent virus arose
at this site. Whether this site was reached after replication in the respiratory tract and propaga-
tion via shedding in oral secretions and swallowing or whether infection occurred simulta-
neously in the two sites remains an open question.
Concerning neurotropism, the viral population sequenced from the CSF of the patient was
HS-dependent while results obtained in 2D and 3D neural cultures were more intricate. In sin-
gle infections, HS-dependent and HS-independent variants revealed similar neurotropic
potential as both showed high replication levels in primary neural cells without significant dif-
ference 5 dpi. However, in competition experiments, HS-independent variants outcompeted
HS-dependent variants 5 dpi while the opposite occurred at earlier time points (1 hpi and 1
dpi in 2D and 4 hpi in 3D cultures). The higher amount of cell-associated HS-dependent
viruses shortly after inoculation is easily explicable by the high expression of HS in neural tis-
sues. However, the fact that the improved binding is not reflected by an improved replicative
fitness 5 dpi is less obvious. A similar situation was observed in Vero cells where the binding
advantage of EV71-VP197R167G did not result in improved replication relative to EV71-V-
P197L167E. Whether another step of the viral life is affected by the VP1 L97R mutation in Vero,
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2D and 3D neural cultures is currently under investigation. Of note in this study and in our
previous publication [39], the HS-dependent variant was fitter in SH-SY5Y neuroblastoma
cells at any time post infection. This difference between primary neural cultures and immortal-
ized cells may rely on the nature of these culture models (cancer neuron precursors for neuro-
blastoma cells versus mature neurons and glial cells for both 2D and 3D neural cultures) and
emphasizes the need to use relevant primary tissue culture models to study viral pathogenesis.
Two explanations may account for the detection of HS-dependent virus only in the patient’s
CSF and our experimental observations that the HS-independent virus outcompetes the HS-
dependent virus in neural tissues 5 dpi (thought both variants replicate to high level in inde-
pendent infections). First, the patient’s CSF may have been sampled shortly after neural inva-
sion, at a time where the HS-dependent variant was also fitter in neural cultures. However, this
would imply that both variants were present together in the CNS where the HS-dependent var-
iants outcompeted the HS-independent variants. The fact that only HS-dependent variants
were found in the patient’s blood does not support this hypothesis. More probably, the ability
to bind HS promoted EV71-VP197R167G replication in HS-enriched tissues (such as the basal
layers of the gastrointestinal mucosa, muscle or endothelial cells), resulting in sustained vire-
mia and subsequent dissemination to neural tissues. In this context, EV71 neurotropism may
not rely on an improved growth in neural tissues but rather on an improved dissemination
ability selected upstream of CNS contamination over the course of an infection.
The implication of HS binding in dissemination and neurotropism has been investigated
for several viruses and remains controversial. Studies on aphtoviruses [47], flaviviruses [48],
togaviruses [49], alphaviruses [50] and even enteroviruses such as coxsackievirus B3 [51] sug-
gest that binding to HS may lower viremia due to virus trapping in tissues expressing high HS
levels, while it may improve neurotropism and ability to cross the blood-brain barrier [52]. Of
note, two recent papers reported that infection by EV71 with VP1 E145Q substitution was
associated with an attenuated phenotype in mice and cynomolgus monkeys and that this atten-
uation was linked to the ability of VP1 145Q to bind HS [31, 34]. The authors conclude that
HS binding and in vivo virulence are negatively correlated due to trapping and abortive infec-
tion of HS-dependent viruses in tissues expressing high levels of HS but low levels of SCARB2.
In the clinical case investigated here, the HS binding variant was the only variant sequenced
from the blood of the patient suggesting that HS binding did not prevent viremia and dissemi-
nation but rather promoted it. Several hypotheses could explain these different observations:
first, mice and monkeys may not faithfully reproduce EV71 infection in human as suggested
by studies showing that isolates with VP1 145G/Q are frequently associated with severe neuro-
logical disease in humans [35–38]; second, the inoculation site may modulate the infection
outcome. Huang and colleagues [53] showed that broad mutant spectra with divergent muta-
tions are observed at the initial infection sites (the respiratory and digestive systems) and that a
selection bottleneck occurs afterwards with subsequent enrichment of advantageous mutations
in the viral population. Intraperitoneal or intravenous injections may thus prevent the natural
evolution of the viral population observed after fecal-oral or respiratory transmission; third,
the binding affinity for HS may differ according to the number and/or location of positive
charges on the viral capsid, and different mutations (VP1 E145Q versus VP1 L97R) may result
in different binding intensities and different trapping strengths; finally, the host immunity cer-
tainly plays a key role. In the clinical case presented here, the patient underwent immunosup-
pressive therapy with rituximab, an anti-CD20 antibody that depletes the peripheral B-cell
pool. Seroneutralisation experiments performed with the patients’ serum at a time when the
VP1 97R mutation was already present in the plasma failed to highlight the presence of an anti-
body-mediated selective immune pressure against HS-dependent and HS-independent vari-
ants [39]. This absence of neutralizing antibodies was correlated with a negative complement
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fixation assay confirming a poor antibody response against enterovirus linked to the immuno-
suppressed state of the patient. Fujii et al showed that viruses with VP1 145E are more resistant
to neutralizing antibodies than viruses with VP1 145G [31]. The absence of immune pressure
may thus be a prerequisite for the emergence of HS-dependent variants in vivo, since critical
residues, such as VP1 98 and 145, seem to play an important role both in immune escape [30,
31] and HS binding [29, 34, 54, 55]. The emergence of HS-dependent mutants and their dis-
semination could thus be favored in the presence of a poor antibody response. Additional clin-
ical investigations are needed to further assess the implication of HS binding in dissemination
and disease severity in humans.
The recent emergence of severe cases associated with EV71 genogroup C1 infections and
the lack of an efficient vaccine or antiviral to fight EV71 infections [56, 57] highlights an
important need for the development of effective antiviral strategies [58]. In this study, we dem-
onstrated the key role of HS attachment receptor binding in EV71 dissemination in an immu-
nocompromised host, and our preliminary results in cells and neural cultures highlighted the
inhibition of HS-dependent variants by soluble HS mimetic compounds. Soluble heparan sul-
fate analogs may thus be a useful tool to limit enterovirus replication and dissemination. In
conclusion, our data may help to unravel the key determinants of EV71 dissemination and




Respiratory (http://www.epithelix.com/products/mucilair) and EpiIntestinal (https://www.
mattek.com/products/epiintestinal/ tissues) were ordered from Epithelix and MatTek biotech-
nology companies. There, the tissues are developed from anonymized samples and after Ethi-
cal approval. The study was conducted according to the Declaration of Helsinki on biomedical
research (Hong Kong amendment, 1989), and the research protocol was approved by our local
ethics committee.
Cells
RD (human rhabdomyosarcoma, ATCC CCL-136) and Vero (monkey kidney, ATCC CRL-
1587) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) and GlutaMAX
(31966021, Gibco, Thermo Fisher Scientific, Switzerland) supplemented with 10% (v/v) fetal
bovine serum (FBS) (P40-37500, Pan Biotech, Chemie Brunschwig, Switzerland) and 100 μg/
ml of penicillin and streptomycin (15140–122, Gibco, Thermo Fisher Scientific, Switzerland).
Caco-2 (human colorectal adenocarcinoma, ATCC HTB 37) and SH-SY5Y cells (human neu-
roblastoma, ATCC CRL- 2266) were grown in Eagle’s minimum essential medium (EMEM)
(BE12-125F, Lonza, Switzerland) and DMEM/F12 medium (31331093, Gibco, Thermo Fisher
Scientific, Switzerland), respectively, supplemented with 2 mM L-glutamine (25030–024,
Gibco, Thermo Fisher Scientific, Switzerland), 1% non-essential amino acids (11140–035,
Gibco, Thermo Fisher Scientific, Switzerland) and 10% (v/v) FBS. HEK 293T/17 (human kid-
ney, ATC C#CRL-11268) cells were grown in DMEM (41965039, Gibco, Thermo Fisher Scien-
tific, Switzerland) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 μg/ ml of
penicillin and streptomycin, 2 mM l-glutamine, 1 mM sodium pyruvate (11360–039, Gibco,
Thermo Fisher Scientific, Switzerland), and 1% non-essential amino acids.
Cultures were maintained at 37˚C in a 5% CO2 atmosphere. Infection medium was similar
but with reduced FBS concentrations (2.5% for Vero and RD cells and 5% for Caco-2 and
SH-SY5Y cells).
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Viral stocks
EV71-VP197L167E and EV71-VP197R167G. The pClVP197L167E and pClVP197R167E infec-
tious clones were ordered from Biomatik (Ontario, Canada) as previously described [39]. The
VP1 E167G mutation was added by site directed mutagenesis as previously described [59]
using 5’GCCAGATTCCAGAGGGTCTCTCGCATGGC3’ forward and 5’GCCATGCGAGA
GACCCTCTGGAATCTGGC3’ reverse primers. Constructs were checked by sequencing, lin-
earized with BamHI, in vitro transcribed and transfected into Vero or Caco-2 cells, as previ-
ously described [39].
Seven days after transfection, supernatants and cells were collected, subjected to 3 freeze-
thaw cycles, clarified by centrifugation (5 min at 1000 rpm) and re-passaged 3 times in 80%
confluent Vero cells. Alternatively, confluent Vero cells were inoculated with supernatant
from infected Caco-2 cells. For the last passage, and when cytopathic effect (CPE) was strong
enough, the infection medium was changed 24 h before collection to obtain only freshly pro-
duced viruses. Supernatants were collected, clarified by centrifugation (5 min at 1000 rpm)
and concentrated by ultracentrifugation as previously described [30]. Ultracentrifuged viral
stocks were aliquoted and stored at -80˚C. VP1 was PCR amplified and sequenced to confirm
the absence of unexpected mutations (see below).
EV71-VP197R/L167G/E. Two viral stocks that contained equimolar amounts of EV71-
VP197R167G and EV71-VP197L167E were used in this study. The first stock was naturally gener-
ated by the emergence of spontaneous mutations during viral stock preparation. The presence
of equimolar amounts of EV71-VP197R167G and EV71-VP197L167E was assessed by Sanger
sequencing and was confirmed by subcloning (pCR2.1-TOPO cloning kit, 45–0641, Invitro-
gen, Thermo Fisher Scientific, Switzerland) and sequencing of VP1 from individual clones.
The second stock was created by mixing equimolar amounts of EV71-VP197R167G and EV71-
VP197L167E. Again, equal representation of the two derivatives was assessed by sequencing with
the same primers. Both stocks were used in ex vivo experiments (in MucilAir, SmallAir, EpiIn-
testinal and neural tissues) while the naturally generated stock was used for binding and infec-
tion assays in vitro.
All viral stocks were quantified by RT-qPCR and titration, according to the Reed and
Munch method [60] and were passaged less than 3 times to exclude any bias linked to cell
adaptation.
Heparinase assay
Confluent Vero, Caco-2, RD or SH-SY5Y cells pre-plated in a 96 well plate, were washed twice
with heparinase III digestion buffer (0.1 M sodium acetate pH 7.0, 1 mM calcium acetate and
0.2% BSA) and incubated for 1 h at 37˚C with 3.5 mIU/ml of heparinase III (AMS.HEP_ENZ
III_S, Amsbio, Switzerland) (50 μl/well). Control samples were incubated with digestion buffer
alone. Heparinase III efficient cleavage was assessed by immunofluorescence with a mouse
anti-Δ-heparan sulfate F69-3G10 antibody (370260-S, Amsbio, Switzerland, diluted 1:500) spe-
cific for a heparan sulfate neo-epitope generated after digestion.
Heparin inhibition assay
EV71-VP197R/L167G/E mixed viral population was pre-incubated with 300 μg/ml of soluble hep-
arin sodium salt from porcine intestinal mucosa (H4784, Sigma-Aldrich, Merck, Switzerland)
diluted in culture medium or with culture medium alone as control for 1 h at 37˚C. Confluent
monolayers of Vero, Caco-2, RD or SH-SY5Y cells were challenged with 50 μl of the pre-incu-
bated virus-heparin or virus-alone mixture and virus binding and replication assays were
performed.
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Virus binding and replication assay
Confluent cells were first seeded in 96-well plates and binding and replication assays were per-
formed 24h later as previously described [39]. Briefly, the medium was removed, cells were
washed with cold binding buffer (Hanks’ Balanced Salt Solution [HBSS, 14175053, Gibco,
Thermo Fisher Scientific, Switzerland] containing 1% BSA [wt/vol] and 0.1% sodium azide
[wt/vol]) and incubated for 1h on ice with 50 μl of viral suspension containing 5108 viral
RNA copies. After removal of unbound virus with 3 washes with 200 μl of cold binding buffer,
cells were either lysed directly in 200 μl of easyMAG lysis buffer to quantify bound viruses by
RT-qPCR or overlaid with fresh culture medium and left an additional day at 37˚C before lysis
and viral load quantification by RT-qPCR. To determine the dominant population in binding
and replication experiment run with EV71-VP197R/L167G/E , the VP1 region was PCR-amplified
and sequenced.
Virus binding to immobilized heparin sepharose beads
Aliquots of 200 μl heparin sepharose beads (ab193268, Abcam, UK) were immobilized to
Pierce cellulose acetate filter spin cups (69702, Thermo Fisher Scientific, Switzerland) by cen-
trifugation at 1500 rpm for 5 min. The beads were then equilibrated with 600 μl of binding
buffer (0.02M Tris-HCl, 0.14M NaCl, pH 7.4) and centrifuged for 5 min at 1500 rpm. Subse-
quently, 100, 200 or 600 μl of viral suspension of EV71-VP197R/L167G/E containing respectively
109, 2109 and 6109 viral RNA copies were added and incubated with the heparin sepharose
beads for 1h at 4˚C with gentle mixing. The flow-through fraction was collected by centrifuga-
tion (5 min at 1500 rpm) and the heparin sepharose beads were washed 5 times with 200 μl of
binding buffer. Bound viral particles were then eluted twice by sequential incubation of 5 min
with 200 μl of elution buffer (0.02M Tri-HCl, 2M NaCl, pH 7.4). The collected fractions
(input, flow-through and eluate) were analyzed by RT-qPCR and VP1 was PCR amplified and
sequenced.
RNA extraction and real time-quantitative polymerase chain reaction
RNA was extracted using the NucliSens easyMAG magnetic beads system (BioMe´rieux,
France) according to the manufacturer’s instructions. RT-qPCR was performed using the
quantitative Entero/Ge/08 assay as previously described [61] in a one-step format using the
QuantiTect Probe RT-PCR Kit (Qiagen, Switzerland) according to the manufacturer’s instruc-
tions in a StepOne Applied Biosystems thermocycler. As a quantitative reference standard for
each run, 10-fold dilution series (from 2.5108 to 2.5105 copies/ml) of the in vitro transcribed
full-length pBMH-EV-D68 was used. The RNAse P housekeeping gene (4316831, Thermo
Fisher Scientific, Switzerland) was quantified by qPCR in binding and replication experiments
to confirm homogeneous cell number.
RT-PCR and sequencing
Retro-transcription was performed using Superscript II (Invitrogen) and either random hex-
amer primers (Roche) or a specific primer (2A-3408-R: 5’CTGGGTTTTGAAAAGCTGA
CC3’) as previously described [39]. The VP1 region was amplified by PCR (Fwd 5’TGCTCGA
GATGGAGTATTCG3’ and Rev 5’CTGGGTTTTGAAAAGCTGACC3’) and nested PCR
(Fwd 5’CGACTACTACACTACAGGCTTGGTTAG3’ and Rev 5’CATTGGGCGAGGTATC
CAC3’) with platinum Taq DNA polymerase (P/N 10966026, Invitrogen, Thermo Fisher Sci-
entific, Switzerland). PCR products were purified as previously described [39] and sequenced
(Fasteris-DNA sequencing service, Switzerland).
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Generation of KO cell lines using CRISPR/Cas9
Two SCARB2 targeting guide RNAs (sgRNA1 5’-CACCGCGATGCTGCTTCTACACGGC-3’
& 3’-CGCTACGACGAAGATGTGCCGCAAA-5’, and sgRNA2 5’-CACCGCCGGCATT
GTCTGACGTAT-3’ & 3’-CGGCCGTAACAGACTGCATACAAA-5’ for the sgRNA2) were
subcloned in the pLentiCRISPRV2 vector (Addgene # 52961). Recombinant lentiviruses (plen-
tiCRISPRV2, pLentiCRISPRV2-SCARB2-sg1 or pLentiCRISPRV2-SCARB2-sg2) were pro-
duced by transient transfection of HEK 293T/17 cells as previously described [62]. Caco-2 and
RD cells (70–80% confluency in 6-well plates) were transduced with 1 ml of viral supernatants.
Five days post transduction the cells were trypsinised and subjected to puromycin selection
(58-58-2, Invivogen, LABFORCE, Switzerland; 10 μg/ml for Caco-2 cells and 6 μg/ml for RD
cells). Cells were maintained in the selection medium and the expression of SCARB2 was
assessed by Western Blot.
Infection of in vitro human reconstituted respiratory (MucilAir, SmallAir)
and small intestine tissues (EpiIntestinal)
Human upper (MucilAir) and lower (SmallAir) airway epithelia (Epithelix, Geneva, Switzer-
land) were developed from isolated nasal polyp and distal lung epithelial cells originating from
surgeries as previously described [40, 41]. Human small intestine tissues (EpiIntestinal) were
purchased from MatTek (Ashland, USA) and are reconstituted from primary human small
intestinal epithelial cells isolated from the ileum of healthy adult donors. After full differentia-
tion, the EpiIntestinal tissues faithfully reproduce the pseudo-stratified architecture of the
human small intestine composed of enterocytes, paneth cells, M cells, tuft cells and intestinal
stem cells [https://www.mattek.com/products/epiintestinal/].
The tissues, cultured at an air-liquid interface (at 33˚C for MucilAir and at 37˚C for the
other tissues), were infected apically or basally as previously described [63]. Briefly, for apical
infection, 108 viral RNA copies (in 100 μl of culture medium) culture medium were applied at
the tissue/air interface while for basal infection, 6108 viral RNA copies (in 600 μl of culture
medium) were applied at the tissue/liquid interface. After 4 hours, residual viruses were
removed by extensive apical or basal washes and then, every day, 200 μl of culture medium
was applied apically for 20 min to collect apically released viruses. Basal medium was also col-
lected daily and replaced with 500 μl of fresh medium. RNA was extracted from apical samples
collected 5 dpi.
Infection of 2D and 3D engineered neural tissues
2D and 3D neural tissues were engineered from human induced pluripotent neural stem cells
(GSC-4311, MTI-GlobalStem, Thermo Fisher Scientific, Switzerland) and contained a mixed
population of mature neurons and glial cells [64]. 2D cultures were inoculated with 107 viral
RNA copies (in 100 μl of culture medium). Residual inoculum was removed after 1 h and
tissues were lysed 1 hpi and 5 dpi for RNA extraction. 3D cultures were inoculated with
4107 viral RNA copies (in 40 μl of medium) and tissues were lysed 4 hpi or 5 dpi for RNA
extraction.
For all tissues, replication was quantified by RT-qPCR and VP1 was PCR amplified and
sequenced in both single infections or competition assays.
Western blot and immunofluorescence (IF)
Antibodies. Mouse anti-HS (F58-10E4, 370255–1, Amsbio, Switzerland, diluted 1:100 in
PBS + 1% BSA), rabbit anti-LIMPII/Igp85 (SCARB2) (PA3-1682, Thermo Fisher Scientific,
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Switzerland, diluted 1:1000), rabbit anti-GFAP (Z0334, Dako, Agilent, Switzerland, diluted
1:100), mouse anti-GFAP (MAB360, Millipore, Merck, Switzerland, diluted 1:50), rabbit anti-
tubulin β-III (Previously Covance Catalog# PRB-435P, Biolegend, Switzerland, diluted 1:1000)
and mouse anti-tubulin β-III (T8660, Sigma-Aldrich, Merck, Switzerland, diluted 1:200) were
used as primary antibodies for IF staining of respectively HS, SCARB2, glial cells and neurons.
Goat anti-mouse Alexa Fluor 594 (A21044, Invitrogen, Thermo Fisher Scientific, Switzerland,
diluted 1:2000), goat anti-mouse Alexa Fluor 594 (A11032, Invitrogen, Thermo Fisher Scien-
tific, Switzerland, diluted 1:2000) and goat anti-rabbit Alexa Fluor 488 (A11008, Invitrogen,
Thermo Fisher Scientific, Switzerland, diluted 1:2000) were used as secondary antibodies. Rab-
bit anti- LIMPII/Igp85 (SCARB2) Ab (diluted 1:1000 in 5% milk/TTBS 0.05%), mouse anti-
EV71 VP2 mAb (MAB979, Millipore, Merck, Switzerland, diluted 1:1000 in 5% milk/TTBS
0.05%) and mouse anti-GAPDH mAb (6C5, sc-32233, Santa Cruz, Switzerland, diluted 1:1000
in 5% milk/TTBS 0.05%) were used as primary antibodies for western blot while anti-rabbit
HRP-labelled Ab (7074, Cell Signaling Technology; diluted 1:1000 in 5% milk/TTBS 0.05%) or
anti-mouse HRP-labelled Ab (7076, Cell Signaling Technology; diluted 1:1000 in 5% milk/
TTBS 0.05%) were used as secondary antibodies.
Western blot
Proteins were loaded on a 10% SDS-PAGE gel, transferred on a PVDF membrane (162–0177,
BIO-RAD, Switzerland) that was hybridized with the primary Ab overnight at 4˚C. The mem-
branes were washed twice with TTBS 0.05% [TBS buffer (10 mM Tris HCl, pH 7.5, 500 mM
NaCl) with 0.05% Tween] for 10 min and incubated for 1 h at 37˚C with the secondary Ab.
The membranes were washed twice with TTBS for 10 min and developed with the ECL system
(34080, Thermo Fisher Scientific, Switzerland) according to the manufacturer’s protocol.
Images were acquired with the Fujifilm LAS 4000 luminescence imager.
IF on cells. Cells plated on coverslips were washed twice with phosphate-buffered saline
(PBS) and fixed for 20 min at room temperature (RT) in a 4% paraformaldehyde solution.
Fixed cells were washed with PBS before incubation for 1 h at 37˚C with the primary Ab.
Intensive PBS washings were performed prior to incubation for 45 min at 37˚C with the sec-
ondary Ab. Cells were then washed 3 times with PBS, stained with 4,6-diamidino-2-phenylin-
dole (DAPI) for 7 min at RT and washed with PBS a final time. Coverslips were mounted in
Fluoroprep mounting medium (BioMe´rieux, France)
IF on paraffin-embedded tissue sections. Paraffin was removed from MucilAir, SmallAir
and EpiIntestinal tissue sections by embedding the sections twice in UltraClear solution
(3905.5000PE, Biosystems, Switzerland) for 3 min and twice in EtOH 96% (E/0600DF/15,
Fisher Chemical, Thermo Fisher Scientific, Switzerland) for 3 min. Sections were then air-
dried for 5 min and quickly immersed in water. Tissues were rinsed with PBS, permeabilized
with 1% Triton (Fluka, Switzerland) for 15 min at RT and incubated with primary antibodies
at 4˚C overnight. Intensive PBS washes were performed prior to incubation with the secondary
antibody for 45 min at 37˚C. Next, tissues were washed 3 times with PBS, stained with DAPI at
RT for 7 min, and washed with PBS a final time. Coverslips were mounted in Fluoroprep
mounting medium (BioMe´rieux, France). Alternatively, tissue sections were counterstained
with Mayer’s Hematoxylin Solution (5 min), eosin (7 min) and mounted with Ne´o Mount
medium (1.09016.0500, Merck, Switzerland). Images were acquired with a Zeiss LSM 700
Meta confocal microscope with the "Plan-Neofluar" 63x/1.4 oil objective and were processed
with the ZEN Blue Advanced Processing and Analysis module.
IF on 2D neural cultures. 2D neural cultures were fixed at RT in 4% PFA for 20 min,
rinsed with PBS permeabilized with 0.1% Triton for 15 min at RT, and embedded in blocking
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buffer (PBS-BSA 10%) before being incubated with primary antibodies at 4˚C overnight. The
cultures were washed with PBS prior to incubation with the secondary antibody for 1 hour at
RT. Goat anti-mouse Alexa Fluor 594 and goat anti-rabbit Alexa Fluor 488 were used as sec-
ondary Ab. After PBS washes, the nuclei were stained with DAPI at RT for 7 min and washed
again with PBS. Coverslips were mounted in Fluoroprep mounting medium (BioMe´rieux,
France). All IF Images were acquired with a Zeiss LSM 700 Meta confocal microscope and
were processed with the ZEN Blue Advanced Processing and Analysis module.
MetaMorph analysis in cell lines and intestinal tissues
Images were acquired on a Zeiss LSM700 confocal microscope with a 63x/1.4 oil objective
leading to the calibration of 0.396 microns per pixel. HS expression was measured with Meta-
Morph software version 7.7.6 (Molecular Devices, Sunnyvale, CA).
Cell lines. Blue (DAPI) and red (HS) or green (SCARB2) color channels were separated
with the ColorSeparate function, and both images were converted to compatible files. A cell
scoring step followed, in which the blue channel was used in “All nuclei” section and the red
or green channel was used as a positive marker with the following respective parameters:
“Approximate min width” (7 and 1 microns), “Approximate max width” (17 and 12 microns),
“Parameter Intensity above local background” (8 and 40 levels). The “Algorithm” parameter
was set to Standard. The cell scoring step reported the “Total Cells” number to ensure the sta-
tistical reliability of measurements, and the parameter “%Positive Cells” to reflect the expres-
sion of the receptor.
Intestinal tissues. Images were acquired as stacks in which four channels/wavelengths
were present (blue: 440 nm; red: 645 nm; green: 510 nm; and transmission light) and four to
six z positions were acquired. Red channel planes were first selected with the Select Plane func-
tion. Two regions of exactly the same size were manually drawn in the image that corre-
sponded to apical and basal areas of the tissue and both areas were measured and stored. Next,
we looped through z planes of the red channel and performed the following actions for each of
the two regions: “Area of the intensity above level 3” was measured as Total Tissue Area; “Area
of the intensity above level 15” was measured as High Intensity Tissue Area; and values of the
“High Intensity Tissue Area” across all z planes were averaged, with values being obtained for
the apical and basal areas.
I-carrageenan inhibition assay
I-carrageenan (C1138, Sigma-Aldrich, Merck, Switzerland) was serially diluted and added for
1h at 37˚C to EV71-VP197R167G, EV71-VP197L167E or EV71-VP197R/L167E/G (multiplicity of
infection [MOI], 0.01 PFU/cell). The mixture was then added to confluent 2D neural cells or
Vero cells grown in a 96-well plate at a density of 13 × 104/well. After 1 h at 37˚C, monolayers
were washed and overlaid with fresh medium. One dpi, viral replication was monitored by
immunocytochemistry (ICC) in Vero cells and by RT-qPCR in neural cells.
For ICC, cells were washed with PBS, fixed with cold methanol:acetone (1:1) for 1 min and
permeabilised with PBS-Triton 0.1% for 5 min on ice. Cells were then incubated 1h at 37˚C
with mouse anti-EV71 VP2 monoclonal antibody (MAB979, Millipore, Merck, Switzerland;
diluted 1:500 in PBS-BSA 1%). After 3 washes with PBS-Triton 0.1%, cells were incubated 1 h
at 37˚C with the anti-mouse HRP-labelled secondary antibody (7076, Cell Signaling Technol-
ogy; diluted 1:1000 in PBS-BSA 1%). After extensive washing, DAB substrate solution (D4293-
50SET, Sigma-Aldrich, Merck, Switzerland) was added for 15 min before final washing with
PBS. More than 400 cells per well were scored under a light microscope. The percent of inhibi-
tion of virus infectivity was determined by comparing the percentage of infected cells in
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presence of increasing concentrations of ı-carrageenan relative to the percent of infected cells
in absence of ı-carrageenan (set as reference at 100%). All data were generated from duplicate
wells in three independent experiments.
For quantification by RT-qPCR, neural cultures were lysed in 200 μl of easyMAG lysis
buffer. RNA was extracted, viral replication was quantified by RT-qPCR and VP1 was PCR
amplified and sequenced. The percent of inhibition of virus infectivity was determined by
comparing the viral load measured in neural cells in presence of increasing concentrations of
ı-carrageenan relative to the viral load measured in absence of ı-carrageenan (set as reference
at 100%).
Statistics
Values are expressed as mean (± SEM). Experiments were performed at least in biological
duplicates, with N in the figure legend indicating the number of replicates. Two-way ANOVA,
Fisher’s exact tests and determination of the fifty percent inhibitory concentration (IC50) was
determined using GraphPad Prism 7.02 software.
Supporting information
S1 Fig. Human SCARB2 is necessary for successful infection by EV71-VP197R167G, EV71-
VP197L167E variants in mouse cells. Mouse L929 cells were transfected with a control plasmid
(pCTL) or a plasmid expressing human SCARB2 (pSCARB2). 24h post transfection, cells were
infected with EV71-VP197R167G or EV71-VP197L167E variants at a MOI = 0.2. 24 h later, cells
were lysed and the expression of SCARB2 and of EV71 VP0 and VP2 proteins were quantified
by western blot. Of note, the antibody used to detect SCARB2 is not specific for human
SCARB2 and recognises endogenous mouse SCARB2.
(TIF)
S2 Fig. Glial cells and mature neurons express HS and SCARB2. Co-localisation of HS
expressing cells (stained in red) with (A) glial cells (stained in green) and (B) neurons (stained
in green). Co-localisation of SCARB2 expressing cells (stained in green) with (C) glial cells
(stained in red) or (D) neurons (stained in red). For each panel subpanel showing cell nuclei
and merged images are also shown. Scale bar = 20 μm.
(TIF)
S1 Text. Exogenous expression of hSCARB2 in mouse cells (L929). The pCWX-UBI-S-
CARB2-PGK-GFP SCARB2 expressing vector was constructed with the Gateway cloning tech-
nology according to the manufacturer’s instruction (Gateway LR Clonase II Enzyme mix,
11791020, Invitrogen, Thermo Fisher Scientific, Switzerland). An LR recombination reaction
was performed between the entry clone containing the SCARB2 coding sequence (pENTR-L1-
SCARB2-L2, Clone ID IOH9776, Invitrogen, Thermo Fisher Scientific, Switzerland), the entry
clone containing the ubiquitin promoter (pENTR-L4-UBI-L1R, gift from Patrick Salmon,
Addgene plasmid # 45959) and the destination vector containing attR sites (pCWX-R4-DEST-
R2-PGK-GFP, kindly provided by Prof. Karl-Heinz Krause, University of Geneva). Sub conflu-
ent mouse L929 cells, were transfected with pCWX-UBI-SCARB2-PGK-GFP or pCLX-U-
BI-GFP (gift from Patrick Salmon, Addgene # 27245). After 24 h, the cells were infected with
EV71-VP197R167G and EV71-VP197L167E at an MOI of 0.2. 24 h post infection cells were lysed
with RIPA (Tris 50 mM- pH 7, NaCl 150 mM, 0.1% SDS, 0.5% Sodium deoxycholate, 1% Tri-
ton X-100) and analysed by Western Blot both for quantification of SCARB2 expression and
to highlight expression of viral protein. To this end, protein were loaded on a 10% SDS-PAGE
gel, transferred on a PVDF membrane (162–0177, BIO-RAD, Switzerland) that was hybridized
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with the primary rabbit anti- LIMPII/Igp85 (SCARB2) Ab (PA3-1682, Thermo Fisher Scien-
tific, Switzerland, diluted 1:1000 in 5% milk/TTBS 0.05%), mouse anti-EV71 VP2 mAb
(MAB979, Millipore, Merck, Switzerland, diluted 1:1000 in 5% milk/TTBS 0.05%) and mouse
anti-GAPDH mAb (6C5, sc-32233, Santa Cruz, Switzerland) overnight at 4˚C. The mem-
branes were incubated for 1 h at 37˚C with the anti-rabbit HRP-labelled secondary antibody
(7074, Cell Signaling Technology; diluted 1:1000 in 5% milk/TTBS 0.05%) or the anti-mouse
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